MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.

    A. Sawal, A. Kumar, A. Singh, K. Alreja, S. Tomar, A. Tiwari (chandigarh, India)

    Objective: To devise a portable skid free mat bearing a combination of patterned and pictographic visual cues for freezing of gait. Background: Freezing of gait…
  • 2025 International Congress

    Enhancing Parkinson’s Nurse Care with AI-Driven Remote Symptom Monitoring

    F. Chmell, P. Lee, M. Sander (München, Germany)

    Objective: This project evaluates how AI-driven continuous monitoring and wearable sensors can support Parkinson’s disease (PD) nurses in optimizing medication schedules, assessing treatment efficacy, and…
  • 2025 International Congress

    Frequency and outcome of PEG tube implantations in hospitalized Parkinson’s disease patients

    R. Burke, T. Mehta, H. Kamo, M. Okun, C. Hess, M. Remz (Gainesville, USA)

    Objective: We aimed to investigate the frequency and outcome of percutaneous endoscopic gastrostomy (PEG) tube implantation in patients with Parkinson’s disease (PD) during United States…
  • 2025 International Congress

    Foscarbidopa/Foslevodopa Therapy Improves Continuous Duration of Good ON Time and Correlated With Quality of Life in People With Parkinson’s Disease

    M. Bouchard, R. Hauser, P. Odin, D. Kern, S. Isaacson, L. Bergmann, L. Harmer, J. Homola, R. Gupta, C. Yan, C. Carroll (North Chicago, USA)

    Objective: To assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on longest consecutive duration of Good and Best ON time and association of…
  • 2025 International Congress

    Exploring Clinical and Neurophysiologic Predictors of Adaptive Deep Brain Stimulation Response in Parkinson’s disease

    T. Herrington, M. Beudel, J. Ostrem, S. Little, A. Ramirez-Zamora, L. Almeida, A. Fasano, T. Hassell, K. Mitchell, E. Moro, M. Gostkowski, N. Sarangmat, L. Tonder, Y. Tan, R. Summers, S. Stanslaski, H. Bronte-Stewart (San Francisco, USA)

    Objective: To evaluate clinical and neurophysiologic characteristics that may predict a positive clinical response to adaptive deep brain stimulation (aDBS) in patients previously stable on…
  • 2025 International Congress

    GT-02287 in Parkinson’s Disease: Interim Data from a Phase 1b Study

    R. Pozzi, T. Ignoni, M. Bosetti, M. Desciscio, A. Evans, V. Fung, A. Lehn, V. Miller, M. Rentería, R. Schwartz, D. Thyagarajan, S. Tisch, J. Taylor, J. Hannestad (Lugano, Switzerland)

    Objective: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease with and without a…
  • 2025 International Congress

    Evaluation of Local Field Potential-guided DBS-programming in a Parkinson’s disease outpatient clinic

    V. Zentsch, N. Warneke, I. Aymanns, D. Putzer, T. Huchtemann, T. Warnecke, I. Claus (Muenster, Germany)

    Objective: To evaluate potential use and applicability of local field potential-guided DBS-programming under real-life conditions in a Parkinson’s disease (PD) outpatient clinic. Background: Deep brain…
  • 2025 International Congress

    Effects of Dynamic Neuro-Cognitive Imagery on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial

    P. Silva, K. Honda, L. Santos, J. Garcia, B. Silva, M. Piemonte (Sao Paulo, Brazil)

    Objective: To compare the effects of an experimental intervention (EI) based on DNI with a control intervention (CI) of equal volume and intensity, excluding MP…
  • 2025 International Congress

    Quercetin Reduces mtDNA Release in PRKN-Deficient and Oxidatively Stressed SH-SY5Y Cells

    G. Agyeah, J. Ghelfi, L. Gallucci, K. Wasner, P. Antony, A. Rakovic, S. Pereira, A. Grünewald (Belval Esch-sur-Alzette, Luxembourg)

    Objective: This study investigates the role of Parkin deficiency in mitochondrial dysfunction and its contribution to mitochondrial DNA (mtDNA) release in Parkinson’s disease (PD). We…
  • 2025 International Congress

    Clinical Progression and Genetic Pathways in Body-First and Brain-First Par-kinson’s Disease

    M. Passaretti, D. Veréb, M. Mijalkov, Y. Chang, H. Zhao, J. Sun, B. Zufiria Gerbolés, G. Volpe, N. Rivera, M. Bologna, J B. Pereira (Stockholm, Sweden)

    Objective: We aim to assess Parkinson's disease (PD) phenotypes across both prodromal and clinical PD stages, track their pathological progression in vivo and identify potential underlying…
  • « Previous Page
  • 1
  • …
  • 203
  • 204
  • 205
  • 206
  • 207
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley